Význam benziodaronu v lécbĕ dny a hyperurikemického syndromu
[The importance of benziodarone in the treatment of gout and hyperuricemic syndrome]
Jazyk čeština Země Česko Médium print
Typ dokumentu anglický abstrakt, časopisecké články
PubMed
2257602
- MeSH
- benzofurany terapeutické užití MeSH
- dnavá artritida krev farmakoterapie MeSH
- kyselina močová krev MeSH
- lidé MeSH
- urikosurika terapeutické užití MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- anglický abstrakt MeSH
- časopisecké články MeSH
- Názvy látek
- benziodarone MeSH Prohlížeč
- benzofurany MeSH
- kyselina močová MeSH
- urikosurika MeSH
The authors pay attention to benziodarone, a representative of the category of benzofurans. They test its effect on the uric acid serum level in normouraemic subjects as well as in hyperuricaemic syndrome and gouty arthritis. The hypouricaemic action of benziodarone (Amplivex-Labaz) is prompt. The maximum drop of uricaemia after Amplivex administration (2 tablets/day) occurs during the first three days. The uric acid level declines by as much as 80% of the baseline value. For long-term treatment 1 tablet per day is sufficient, in some instances even 1 tablet twice a week. The tolerance of the preparation is satisfactory. The authors deal also with the mechanism of action of benziodarone. Amplivex is not only a uricostatic but also a uricosuric agent.